Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Bimalangshu Dey, M.D.

Co-Author

This page shows the publications co-authored by Bimalangshu Dey and Thomas Spitzer.
Connection Strength

5.847
  1. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2007 Jul; 40(1):19-27.
    View in: PubMed
    Score: 0.378
  2. Current status of haploidentical stem cell transplantation. Br J Haematol. 2006 Nov; 135(4):423-37.
    View in: PubMed
    Score: 0.363
  3. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2005 Feb; 128(3):351-9.
    View in: PubMed
    Score: 0.324
  4. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003 May; 9(5):320-9.
    View in: PubMed
    Score: 0.287
  5. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(11):604-12.
    View in: PubMed
    Score: 0.244
  6. Declining bone marrow harvest quality over 24 years: a single institution experience. Bone Marrow Transplant. 2021 Apr; 56(4):983-985.
    View in: PubMed
    Score: 0.242
  7. Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned. Transplantation. 2019 11; 103(11):2366-2372.
    View in: PubMed
    Score: 0.225
  8. Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. Blood. 2019 07 11; 134(2):211-215.
    View in: PubMed
    Score: 0.218
  9. Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation. Transfus Med Rev. 2019 01; 33(1):43-50.
    View in: PubMed
    Score: 0.210
  10. Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine (Baltimore). 1998 Sep; 77(5):355-69.
    View in: PubMed
    Score: 0.207
  11. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant. 2018 02; 53(2):129-137.
    View in: PubMed
    Score: 0.195
  12. Hematopoietic Stem-Cell Transplantation in the Resource-Limited Setting: Establishing the First Bone Marrow Transplantation Unit in Bangladesh. J Glob Oncol. 2018 09; 4:1-10.
    View in: PubMed
    Score: 0.184
  13. Engraftment syndrome after allogeneic hematopoietic cell transplantation in adults. Am J Hematol. 2014 Jul; 89(7):698-705.
    View in: PubMed
    Score: 0.153
  14. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 May; 20(5):730-4.
    View in: PubMed
    Score: 0.151
  15. Chronic graft-versus-host disease with skin signs suspicious for squamous cell carcinoma. Acta Oncol. 2013 Aug; 52(6):1213-4.
    View in: PubMed
    Score: 0.139
  16. The expanding frontier of hematopoietic cell transplantation. Cytometry B Clin Cytom. 2012 Sep; 82(5):271-9.
    View in: PubMed
    Score: 0.136
  17. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2012 Mar 01; 119(9):1972-80.
    View in: PubMed
    Score: 0.131
  18. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation. 2011 Mar 27; 91(6):672-6.
    View in: PubMed
    Score: 0.124
  19. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010 Oct 27; 90(8):905-11.
    View in: PubMed
    Score: 0.120
  20. Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and peripheral-blood monocytosis. N Engl J Med. 2009 Sep 10; 361(11):1099-106.
    View in: PubMed
    Score: 0.111
  21. Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant. 2008 Sep; 42(5):329-35.
    View in: PubMed
    Score: 0.103
  22. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007 Jul; 13(7):838-43.
    View in: PubMed
    Score: 0.095
  23. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant. 2003 Jun; 9(6):373-82.
    View in: PubMed
    Score: 0.072
  24. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation. 2003 May 27; 75(10):1748-51.
    View in: PubMed
    Score: 0.072
  25. Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2020 12; 55(12):2319-2321.
    View in: PubMed
    Score: 0.058
  26. Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. Bone Marrow Transplant. 2020 04; 55(4):758-762.
    View in: PubMed
    Score: 0.056
  27. A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
    View in: PubMed
    Score: 0.056
  28. Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 09; 24(9):1836-1840.
    View in: PubMed
    Score: 0.051
  29. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clin Cancer Res. 2018 09 01; 24(17):4098-4109.
    View in: PubMed
    Score: 0.051
  30. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2018 04 10; 2(7):745-753.
    View in: PubMed
    Score: 0.050
  31. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. Oncologist. 2018 05; 23(5):624-630.
    View in: PubMed
    Score: 0.049
  32. Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
    View in: PubMed
    Score: 0.046
  33. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
    View in: PubMed
    Score: 0.045
  34. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8.
    View in: PubMed
    Score: 0.043
  35. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):80-5.
    View in: PubMed
    Score: 0.042
  36. Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015 Aug; 50(8):1119-24.
    View in: PubMed
    Score: 0.041
  37. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer. 2015 Mar 15; 121(6):951-9.
    View in: PubMed
    Score: 0.040
  38. Patients' and family caregivers' (FC) quality of life (QOL) and mood during hospitalization for hematopoietic stem cell transplantation (HCT). J Clin Oncol. 2014 Nov; 32(31_suppl):160.
    View in: PubMed
    Score: 0.040
  39. Prognostic understanding, quality of life (QOL), and mood in patients undergoing hematopoietic stem cell transplantation (HCT). J Clin Oncol. 2014 Nov; 32(31_suppl):219.
    View in: PubMed
    Score: 0.040
  40. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8.
    View in: PubMed
    Score: 0.039
  41. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80.
    View in: PubMed
    Score: 0.036
  42. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1190-6.
    View in: PubMed
    Score: 0.036
  43. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7.
    View in: PubMed
    Score: 0.036
  44. Expression of a4ß7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplant. 2013 Apr; 48(4):598-603.
    View in: PubMed
    Score: 0.034
  45. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8.
    View in: PubMed
    Score: 0.034
  46. Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant. 2011 Jun; 11(6):1236-47.
    View in: PubMed
    Score: 0.031
  47. High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leuk Lymphoma. 2011 Jul; 52(7):1363-6.
    View in: PubMed
    Score: 0.031
  48. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67.
    View in: PubMed
    Score: 0.030
  49. Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1025-31.
    View in: PubMed
    Score: 0.029
  50. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
    View in: PubMed
    Score: 0.029
  51. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1447-54.
    View in: PubMed
    Score: 0.028
  52. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant. 2009 Sep; 9(9):2126-35.
    View in: PubMed
    Score: 0.028
  53. High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion. 2009 May; 49(5):995-1002.
    View in: PubMed
    Score: 0.027
  54. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2009 Jan; 43(1):37-42.
    View in: PubMed
    Score: 0.026
  55. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008 Jan 24; 358(4):353-61.
    View in: PubMed
    Score: 0.025
  56. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008 Mar; 41(6):523-9.
    View in: PubMed
    Score: 0.025
  57. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol. 2007 Jul; 35(7):1140-52.
    View in: PubMed
    Score: 0.024
  58. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan; 13(1):82-9.
    View in: PubMed
    Score: 0.023
  59. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant. 2006 Sep; 6(9):2121-33.
    View in: PubMed
    Score: 0.022
  60. My most interesting cases. Clin Transpl. 2006; 580-2.
    View in: PubMed
    Score: 0.022
  61. Cellular immune therapy for refractory cancers: novel therapeutic strategies. Exp Hematol. 2005 Dec; 33(12):1427-35.
    View in: PubMed
    Score: 0.021
  62. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation. 2002 Nov 27; 74(10):1405-9.
    View in: PubMed
    Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.